We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer Calls for Guidance on Misleading Biosimilar-Related Communications
Pfizer Calls for Guidance on Misleading Biosimilar-Related Communications
In a citizen petition filed Monday, Pfizer asked the FDA to issue draft guidance to prevent misleading communications by reference drug sponsors on the effectiveness of biosimilars.